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thank the program committee for the opportunity to discuss this
paper. And, thank you to Dr Humphries for providing the manu-
script to me prior to the meeting.
Dr Humphries and her colleagues at UC Davis have per-
formed a retrospective analysis of their experience using balloon-
expandable stents for the treatment of common iliac artery disease.
They have compared their experience with covered balloon-
expandable and bare-metal balloon expandable stents in 162
patients and 254 arteries treated over a 6.5-year period.
The vast majority (75%) of these were patients treated with
balloon-expandable bare-metal stents. Only 25% of patients were
treated with covered stents. They had a mean follow-up of
22 months. And, as she showed, a signiﬁcantly higher proportion
of patients in the bare metal stent group presented with CLI.
Their results showed that primary, assisted-primary, and sec-
ondary patency were signiﬁcantly better for bare-metal stents
compared with covered stents. This was irrespective of TASC clas-
siﬁcation, lesion length, or adjunctive procedures performed above
or below the inguinal crease. Mortality and limb salvage were not
statistically different between the two groups. However, I was
saddened to see that two patients who initially presented with clau-
dication ended up requiring amputations.
Their results are in direct contrast to multiple other studies
which have shown improved outcomes in the common iliac
segment using covered BE stents. The COBEST trial was a pro-
spective, multicenter, randomized controlled trial published in
JVS in 2011 from Australia that showed signiﬁcantly less restenosis
and fewer reinterventions in the group treated with covered stents.
Their subgroup analysis showed that patients with TASC C and D
lesions actually did the best with covered stents. Similar results
were found in other series as well. So, I have just fourteen ques-
tions for you. No, actually I only have four.
First, you found an equally small number of stents in each
group that experienced thrombosis. If that is true, then what
was the primary method of failure in the covered stent group?
Were these lesions at the proximal or distal ends of the stent grafts
or de novo lesions? And, since you were following these patients
closely with DUS, were their differences in ﬂow velocities on
follow-up duplex that could have identiﬁed those stents at risk of
failure?
Second, more patients in the bare-metal group underwent
concomitant SFA interventions. Despite the fact that this did not
quite reach statistical signiﬁcance, is it possible that these patients
had improved outﬂow that accounted for the improved patency?
Similarly, do you have any information on the degree of disease
in the hypogastric or external iliac artery that could be of
relevance?
Third, how do you account for the completely opposite results
from the ﬁndings of other studies that show superior patency rates
of covered stents in this population? Typically, we see patients
with CLI have worse outcomes than patients with claudication;however, you had much higher percentage of CLI patients that
received bare-metal stents. The COBEST trial had less that 6%
of self-expanding bare-metal stents in their cohort, so that is not
a great explanation for the discrepant ﬁndings.
Finally, what is your recommendation for me the next time I
succeed in recannalizing a TASC D CIA lesion? Should I follow
your data or those of many others?
I enjoyed reading your paper and again appreciate the oppor-
tunity to discuss this paper.
Dr Misty D. Humphries. Thank you for the questions. I will
address them in the order presented.
We did not assess the speciﬁc failure mode for each either
group, although those patients with repeat interventions have an-
giograms that can be reviewed. The presumed mechanism for fail-
ure for covered stents is thought to be at the ends of the stents vs
bare-metal stents, which develop diffuse stenosis throughout the
stent. Although most patients are followed with duplex ultrasound,
documentation of the speciﬁc mode of failure was not recorded. As
a follow-up to this work, we would like to investigate the mecha-
nism of failure for both stent types as well as the difference between
stent restenosis and patency.
As far as differences based on outﬂow disease, we attempted to
characterize procedures as multiple intervention procedures
involving the supra- and/or infrainguinal region vs single-interven-
tion procedures involving only the common iliac segment. No dif-
ference was found in the outcomes for patients with multiple
interventions compared to those with only single interventions,
but we did not look at all angiograms to speciﬁcally assess the
femoral outﬂow. Unfortunately, we do not have angiographic eval-
uation of the SFA in all patients. We could go back to evaluate the
internal iliac arteries, but in all these patients, the external iliac ar-
teries were either treated or patent. Therefore, utility of reporting
the internal iliac arteries speciﬁcally is unclear. As far as the degree
of disease in the iliac arteries, the TASC class reported here is based
on the iliac angiography and we found no difference in the out-
comes with worsening TASC classiﬁcation.
Our work is in opposition to the only RCT on covered vs
bare-metal stents, but we evaluated the group by patency. Other
studies have looked at binary restenosis and used duplex ultra-
sound criteria that may or may not be considered a stenosis in a
stented region by those of us in this room. Covered stents develop
less binary restenosis according to the COBEST trial, but not all
patients get a reintervention immediately when they develop a
duplex identiﬁed stenosis that is >250cm/sec. A stenosis at this
level may be watched for progression or the development of recur-
rent symptoms before a patient gets a reintervention. Our work
presents pragmatic results of bar- metal and covered stents. We
are showing that in a typical practice, bare-metal stents are used
more frequently and the patency is not worse than covered stents.
Finally, the next time you recanalize a stenosis for a TASC D
CIA lesion, consider my work as a guide for you but not a deﬁn-
itive answer. I do not think I can tell you to use a covered stent or a
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ness of covered and uncovered stents, which we are working on.
Patency captures the initial reintervention the patient has after
stent placement, but if two or three interventions are needed to
maintain the patency for a bare-metal stent, the lower cost may
not be justiﬁed. How much do these repeat procedures cost? We
don’t know the answers to these questions and we need to in order
to make a deﬁnitive recommendation about what stents should be
used in the common iliac arteries and all peripheral arteries. Our
work simply shows that with regard to patency, bare-metal stentsare not necessarily worse than covered. It also pushes the question
of how do we translate data from randomized control trials into
practice, and whether we should use data from trials that consider
outcomes we may not agree with to inﬂuence our practice. The
DISCOVER trial that is ongoing in The Netherlands may be
able to answer the question of which stents develop stenosis, but
again, these types of explanatory trials can’t always translate into
the pragmatic setting that we practice in. Until a more comprehen-
sive approach to evaluating restenosis, patency, reinterventions,
and cost effectiveness is available, my practice will not change.
